- Home
- OPCH vs NUVL Comparison
OPCH vs NUVL Comparison
Compare OPCH & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPCH
- NUVL
- Stock Information
- Founded
- OPCH N/A
- NUVL 2017
- Country
- OPCH United States
- NUVL United States
- Employees
- OPCH N/A
- NUVL N/A
- Industry
- OPCH Medical/Nursing Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- OPCH Health Care
- NUVL Health Care
- Exchange
- OPCH Nasdaq
- NUVL Nasdaq
- Market Cap
- OPCH 5.3B
- NUVL 5.6B
- IPO Year
- OPCH N/A
- NUVL 2021
- Fundamental
- Price
- OPCH $33.42
- NUVL $70.25
- Analyst Decision
- OPCH Buy
- NUVL Strong Buy
- Analyst Count
- OPCH 7
- NUVL 10
- Target Price
- OPCH $33.00
- NUVL $113.10
- AVG Volume (30 Days)
- OPCH 1.7M
- NUVL 464.1K
- Earning Date
- OPCH 04-22-2025
- NUVL 02-27-2025
- Dividend Yield
- OPCH N/A
- NUVL N/A
- EPS Growth
- OPCH N/A
- NUVL N/A
- EPS
- OPCH 1.23
- NUVL N/A
- Revenue
- OPCH $4,998,202,000.00
- NUVL N/A
- Revenue This Year
- OPCH $10.06
- NUVL N/A
- Revenue Next Year
- OPCH $8.56
- NUVL N/A
- P/E Ratio
- OPCH $27.33
- NUVL N/A
- Revenue Growth
- OPCH 16.17
- NUVL N/A
- 52 Week Low
- OPCH $21.39
- NUVL $61.80
- 52 Week High
- OPCH $34.85
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- OPCH 63.10
- NUVL 36.80
- Support Level
- OPCH $33.34
- NUVL $69.95
- Resistance Level
- OPCH $34.85
- NUVL $73.24
- Average True Range (ATR)
- OPCH 0.94
- NUVL 3.27
- MACD
- OPCH -0.14
- NUVL -0.70
- Stochastic Oscillator
- OPCH 62.86
- NUVL 29.13
About OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders among others.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.